EP07: Decoding APS: Essential Knowledge for Better Care

This episode focuses on Antiphospholipid Syndrome (APS), a complex condition affecting about 2% of the population, predominantly women of childbearing age.

Decoding APS: Essential Knowledge for Better Care

Werfen is dedicated to Powering Patient Care and increasing global awareness about thrombosis to improve health outcomes. This episode focuses on Antiphospholipid Syndrome (APS), a complex condition affecting about 2% of the population, predominantly women of childbearing age.

Introduction to APS

APS is a systemic autoimmune disease characterized by recurrent thrombotic events in arteries, veins, or small vessels and/or spontaneous early miscarriages with maternal morbidity, caused by persistent antiphospholipid antibodies (aPL).

Pathophysiology

The precise mechanisms by which aPLs lead to thrombosis are not fully understood. It is believed that these antibodies interfere with the normal function of phospholipids in the blood, essential for coagulation, leading to an increased risk of blood clot formation.

Clinical Manifestations

Approximately 40-70% of APS patients experience thrombotic episodes, either venous or arterial. Common manifestations include Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, Transient Ischemic Attacks (TIA), and Pregnancy Morbidity. Other symptoms may include livedo reticularis, skin ulcers, thrombocytopenia, hemolytic anemia, valvular heart disease, and nephropathy.

Diagnosis

APS diagnosis requires positivity in at least one of the following tests: Lupus Anticoagulant (LA), anti-cardiolipin (aCL) IgG or IgM antibodies, and anti-beta2- glycoprotein I (aβ2GPI) IgG or IgM antibodies. Confirmation is needed 12 weeks after the initial positive result, repeating all five assays. Triple positivity indicates a significantly higher thrombotic risk.

Considerations for the Laboratory

The term Lupus Anticoagulant is misleading, as it prolongs coagulation times in vitro but is actually linked to thrombosis and pregnancy complications in vivo. No single coagulation test is sensitive to all LAs, so ISTH recommends performing both dRVVT and APTT assays for better identification. ELISA is the most common method for detecting aCL and aβ2GPI antibodies, though various solid-phase assays, including chemiluminescence and FEIA, offer undisputed advantages with their consistent and automated results.

Treatment

Anticoagulation therapy is crucial for APS. Besides warfarin, agents like LMWH or Fondaparinux are considered alternatives due to therapy failure or patient convenience. Recently, DOACs have also been explored for prophylaxis in several countries. However, due to concerns about increased thrombotic events, especially in high-risk patients, their use is often limited and closely monitored.

Effect of Anticoagulant Drugs on LAC Diagnosis

Any type of anticoagulant, whether oral or parenteral, inevitably prolongs the coagulation times, complicating LA interpretation. Knowing patient's therapy is crucial for accurate analysis, and this information should always accompany the test request.

Prognosis and Complications

APS prognosis varies based on the severity and frequency of thrombotic events. Catastrophic APS (CAPS), a severe form of the syndrome, is associated with high mortality rates and requires aggressive treatment, including anticoagulation, corticosteroids, and plasma exchange or intravenous immunoglobulin (IVIG).

Conclusions and Outlook

APS is a challenging condition that demands precise diagnosis and management to prevent recurrent thrombotic events and minimize complications. By raising awareness and delivering comprehensive care, we can better address the complexities of this syndrome, ultimately leading to more effective patient outcomes.